| Latest Manhattan Pharmaceuticals News Headlines |
| Date | Time | Source | |
| 07/10/2007 | 7:00AM | PRNUS | Manhattan Pharmaceuticals Provides Update on Clinical Pipeline
- Preliminary Phase 3 European clinical results for Altoderm(TM) expected 3Q07
NEW YORK, July 10 /PRNewswire-FirstCall/ -- Manhattan Pharmaceuticals, Inc. (AMEX:MHA) today provided an update regarding the company's pipeline. As announced yesterday, the company intends to continue with the advancement of its four clinical... More...>> |
| 07/09/2007 | 4:30PM | PRNUS | Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
- Results Fail to Demonstrate Meaningful Placebo Adjusted Weight Loss; Obesity Program to be Discontinued
NEW YORK, July 9 /PRNewswire-FirstCall/ -- Manhattan Pharmaceuticals, Inc. (AMEX:MHA) today announced results of the company's two Phase 2a clinical trials of oral Oleoyl-estrone (OE). The results of both randomized... More...>> |
| 06/27/2007 | 7:59AM | PRNUS | Manhattan Pharmaceuticals Acquires Hedrin(TM) for the Treatment of Head Lice
NEW YORK, JUNE 27 /PRNewswire-FirstCall/ -- Manhattan Pharmaceuticals, Inc. (AMEX:MHA) today announced that it has acquired exclusive, North American rights to develop and commercialize Hedrin(TM), a novel, non-insecticide product candidate for the treatment of head lice. Hedrin is currently marketed in Europe and... More...>> |
| 05/10/2007 | 8:29AM | PRNUS | Manhattan Pharmaceuticals Successfully Completes Dosing Portion of Two Phase 2a Clinical Trials of Oral Oleoyl-estrone for Obesi
Results For Both Trials Expected Mid 2007
NEW YORK, May 10 /PRNewswire-FirstCall/ -- Manhattan Pharmaceuticals, Inc. (AMEX:MHA) today announced it has successfully completed patient dosing in two separate, ongoing Phase 2a clinical trials of oral Oleoyl-estrone (OE). The first trial is evaluating OE for the treatment... More...>> |
| 04/04/2007 | 8:29AM | PRNUS | Manhattan Pharmaceuticals Announces License Agreement and Expanded Pipeline
Company Acquires Two New Clinical-Stage Drug Candidates
NEW YORK, APRIL 4 /PRNewswire-FirstCall/ -- Manhattan Pharmaceuticals, Inc. (AMEX:MHA) today announced that it has acquired exclusive, North American rights to develop and commercialize two novel product candidates from Thornton & Ross Limited - the largest independent... More...>> |
| 04/02/2007 | 8:29AM | PRNUS | Manhattan Pharmaceuticals Completes $8.6 Million Private Placement
NEW YORK, April 2 /PRNewswire-FirstCall/ -- Manhattan Pharmaceuticals, Inc. (AMEX:MHA) today announced it completed a private placement of common stock and warrants with certain institutional and other accredited investors. The company expects to use the net proceeds for general corporate purposes.
The company sold... More...>> |
| 03/27/2007 | 8:29AM | PRNUS | AMEX Accepts Manhattan Pharmaceuticals' Plan to Regain Compliance With Continued Listing Standards
NEW YORK, March 27 /PRNewswire-FirstCall/ -- Manhattan Pharmaceuticals, Inc. (AMEX:MHA) today announced that the American Stock Exchange (AMEX) has accepted the Company's plan to regain compliance with continued listing standards of AMEX. The Company's plan was submitted in response to a letter from AMEX which informed... More...>> |
| 02/21/2007 | 8:29AM | PRNUS | Manhattan Pharmaceuticals Completes Enrollment in Phase 2a Study of Oral Oleoyl-estrone for Obesity
NEW YORK, Feb. 21 /PRNewswire-FirstCall/ -- Manhattan Pharmaceuticals, Inc. (AMEX:MHA) today announced it completed patient enrollment in its first Phase 2a multi-center, international clinical study evaluating the safety and preliminary efficacy of oral Oleoyl-estrone (OE) for the treatment of obesity. This randomized... More...>> |
| 11/08/2006 | 8:29AM | PRNUS | Manhattan Pharmaceuticals Expands Phase 2a Obesity Clinical Trial Sites to US
NEW YORK, Nov. 8 /PRNewswire-FirstCall/ -- Manhattan Pharmaceuticals, Inc. (AMEX:MHA) today announced that it has expanded the clinical trial sites for its ongoing Phase 2a study of oral Oleoyl-estrone (OE) in obese adult subjects to the United States. OE is the Company's orally administered product candidate in development... More...>> |
| 11/08/2006 | 8:29AM | PRNUS | Manhattan Pharmaceuticals Expands Phase 2a Obesity Clinical Trial Sites to US
NEW YORK, Nov. 8 /PRNewswire-FirstCall/ -- Manhattan Pharmaceuticals, Inc. (AMEX:MHA) today announced that it has expanded the clinical trial sites for its ongoing Phase 2a study of oral Oleoyl-estrone (OE) in obese adult subjects to the United States. OE is the Company's orally administered product candidate in development... More...>> |
| 10/12/2006 | 8:29AM | PRNUS | Manhattan Pharmaceuticals Expanding Oral Oleoyl-estrone Clinical Program to Include Morbidly Obese
Phase 2a Study to be Initiated at St. Luke's-Roosevelt Hospital, University Hospital of Columbia University
NEW YORK, Oct. 12 /PRNewswire-FirstCall/ -- Manhattan Pharmaceuticals, Inc. (AMEX:MHA) today announced expansion of its oral Oleoyl-estrone (OE) clinical obesity program to include the morbidly obese. A new US... More...>> |
| 06/29/2006 | 10:29AM | PRNUS | Manhattan Pharmaceuticals Doses First Patient Group In Phase IIa Trial For OE, Its Oral Obesity Drug Candidate
NEW YORK, June 29 /PRNewswire-FirstCall/ -- Manhattan Pharmaceuticals, Inc. (AMEX:MHA) today announced that it commenced dosing the first group of patients in its Phase IIa clinical trial of oral Oleoyl-estrone (OE), the company's novel drug candidate for the treatment of obesity. Patient recruitment is ongoing.
The... More...>> |
| 05/16/2006 | 8:02AM | PRNUS | Manhattan Pharmaceuticals Receives SwissMedic's Approval to Commence Phase IIa Trial With OE, Its Oral Obesity Drug Candidate
NEW YORK, May 16 /PRNewswire-FirstCall/ -- Manhattan Pharmaceuticals, Inc. (AMEX:MHA) today reported receipt of Swiss regulatory approval to commence its Phase IIa study with oral Oleoyl-estrone (OE), the company's drug candidate for the treatment of obesity.
The single center, Phase IIa study is a randomized, double-blind... More...>> |
| 12/28/2005 | 11:25AM | PRNUS | Manhattan Pharmaceuticals' Topical Psoriasis Treatment in Phase IIa Trial
NEW YORK, Dec. 28 /PRNewswire-FirstCall/ -- Manhattan Pharmaceuticals, Inc. (AMEX:MHA) reported that a Phase IIa study has been initiated with PTH (1-34), its experimental product for the topical treatment of psoriasis. The investigator-initiated study is being conducted at Boston University Medical Center.
The double-blinded... More...>> |